Living with depression can be overwhelming, especially when traditional treatments fall short. At Peak Interactive Wellness in Colorado, we offer Spravato® (esketamine)—a groundbreaking FDA-approved therapy providing new hope for those with treatment-resistant depression.
Spravato® is a nasal spray form of esketamine, a derivative of ketamine, approved by the FDA for adults with treatment-resistant depression (TRD). Unlike conventional antidepressants that target serotonin or norepinephrine, Spravato® works on the brain's glutamate system, promoting rapid improvements in mood and cognition.
Rapid Symptom Relief: Clinical studies have shown that Spravato® can alleviate depressive symptoms within 24 hours of the first dose.
Effective Monotherapy: As of early 2025, the FDA has approved Spravato® as a standalone treatment for TRD, offering flexibility for patients who cannot tolerate oral antidepressants.
Proven Efficacy: In a pivotal study, 22.5% of patients achieved remission after four weeks of Spravato® treatment, compared to 7.6% with placebo.
Sustained Improvement: Long-term studies indicate that Spravato® helps maintain symptom relief and reduces the risk of relapse when used consistently.
Spravato® is designed for adults who have not responded to at least two different antidepressant treatments. It's administered under medical supervision in a certified clinical setting, ensuring safety and efficacy.
At Peak Interactive Wellness, our dedicated team is committed to providing personalized mental health care. Our certified providers ensure a supportive environment for your Spravato® treatment journey.
If you're struggling with depression and seeking effective treatment options, Spravato® may offer the relief you need. Contact Peak Interactive Wellness today to learn more and schedule your consultation.
Note: Spravato® is available only through a restricted program called the Spravato® Risk Evaluation and Mitigation Strategy (REMS) due to potential risks. Our clinic is certified to administer this treatment safely.